株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性冠症候群:パイプライン製品の分析

Acute Coronary Syndrome - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232806
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
急性冠症候群:パイプライン製品の分析 Acute Coronary Syndrome - Pipeline Review, H2 2016
出版日: 2016年11月09日 ページ情報: 英文 109 Pages
概要

急性冠症候群とは、急激な心臓への血流低下によって引き起こされるあらゆる状態を指し、胸あるいは左上腕部、あごなど身体の一部の痛み、悪心、嘔吐、呼吸困難などの症状があります。年齢や高血圧、高血中コレステロール、喫煙、2型糖尿病、などが素因であり、治療法には、ベータ遮断薬、カルシウム拮抗薬、コレステロール降下剤、ACE(アンジオテンシン変換酵素)阻害薬、ARB(アンジオテンシン受容体拮抗薬)などの投与があります。

当レポートでは、世界における急性冠症候群治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

急性冠症候群の概要

治療薬の開発

  • パイプライン製品の概要

急性冠症候群:企業で開発中の治療薬

急性冠症候群:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

急性冠症候群:企業で開発中の製品

急性冠症候群の治療薬開発に従事している企業

  • advanceCor GmbH
  • Arena Pharmaceuticals, Inc.
  • Artery Therapeutics, Inc.
  • Athera Biotechnologies AB
  • Bayer AG
  • Cardiome Pharma Corp.
  • Cerenis Therapeutics Holding SA
  • CSL Limited
  • Esperion Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • 日本たばこ産業
  • Lee's Pharmaceutical Holdings Limited
  • MedImmune, LLC
  • Pfizer Inc.
  • The Medicines Company

急性冠症候群:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

急性冠症候群:最近のパイプライン動向

急性冠症候群:休止中のプロジェクト

急性冠症候群:開発が中止された製品

急性冠症候群:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8635IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Coronary Syndrome - Pipeline Review, H2 2016, provides an overview of the Acute Coronary Syndrome (Cardiovascular) pipeline landscape.

Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high blood pressure, high blood cholesterol, cigarette smoking and Type 2 diabetes. Treatment includes beta blockers, calcium channel blockers, cholesterol-lowering drugs and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBS).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Coronary Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Coronary Syndrome (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 3, 9 and 1 respectively.Acute Coronary Syndrome.

Acute Coronary Syndrome (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Coronary Syndrome (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Coronary Syndrome (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Coronary Syndrome (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Coronary Syndrome (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Coronary Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Acute Coronary Syndrome - Overview
  • Acute Coronary Syndrome - Therapeutics under Development by Companies
  • Acute Coronary Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acute Coronary Syndrome - Products under Development by Companies
  • Acute Coronary Syndrome - Companies Involved in Therapeutics Development
    • advanceCor GmbH
    • Arena Pharmaceuticals, Inc.
    • Ascendia Pharmaceuticals LLC
    • Athera Biotechnologies AB
    • Bayer AG
    • Cardiome Pharma Corp.
    • Cerenis Therapeutics Holding SA
    • CSL Limited
    • Esperion Therapeutics, Inc.
    • HitGen LTD
    • Japan Tobacco Inc.
    • Lee's Pharmaceutical Holdings Limited
    • LipimetiX Development Inc
    • MedImmune LLC
    • Pfizer Inc.
    • The Medicines Company
    • Verseon Corporation
  • Acute Coronary Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 4-WF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2802 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologics for Acute Coronary Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CER-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clopidogrel bisulphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COR-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalcetrapib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDCO-216 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-6012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PC-mAb - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06282999 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PR-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • temanogrel hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tirofiban hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Coronary Syndrome - Dormant Projects
  • Acute Coronary Syndrome - Discontinued Products
  • Acute Coronary Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Sep 01, 2016: FDA Approves New AGGRASTAT Product Format
      • Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule
      • Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
      • Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
      • Jul 07, 2016: Medicure Receives Response Letter from FDA on AGGRASTAT sNDA for New Indication
      • May 11, 2016: Medicure Files Application for New AGGRASTAT Product Format
      • Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
      • Apr 25, 2016: Patent Term for Rivaroxaban Extended in US
      • Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy
      • Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015
      • Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients
      • Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
      • Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
      • May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Coronary Syndrome, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2016
  • Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
  • Acute Coronary Syndrome - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016
  • Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2016
  • Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2016
  • Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H2 2016
  • Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
  • Acute Coronary Syndrome - Pipeline by CSL Limited, H2 2016
  • Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2016
  • Acute Coronary Syndrome - Pipeline by HitGen LTD, H2 2016
  • Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H2 2016
  • Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Acute Coronary Syndrome - Pipeline by LipimetiX Development Inc, H2 2016
  • Acute Coronary Syndrome - Pipeline by MedImmune LLC, H2 2016
  • Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2016
  • Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2016
  • Acute Coronary Syndrome - Pipeline by Verseon Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Coronary Syndrome - Dormant Projects, H2 2016
  • Acute Coronary Syndrome - Dormant Projects (Contd..1), H2 2016
  • Acute Coronary Syndrome - Discontinued Products, H2 2016
  • Acute Coronary Syndrome - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Acute Coronary Syndrome, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top